Immix Biopharma reported cash from operations of -$11.74M and free cash flow of -$11.76M for the quarter ended Jun 2026, down 121.0% year over year. This cash flow statement covers 23 quarters of results from Dec 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||
| Net Income | -0.40M | -17.63M | -1.33M | -1.56M | -1.54M | -2.05M | -2.50M | -3.60M | -4.34M | -0.82M | -5.33M | -4.41M | -7.15M | 1.27M | -4.54M | -6.62M | -7.59M | -2.41M | -10.09M | -11.56M | |||
| Share-based Compensation | 0.06M | 28.08M | 1.33M | 1.19M | 1.77M | 0.23M | 1.77M | 1.77M | 2.51M | 1.05M | 2.51M | 4.00M | 4.01M | 0.71M | 4.09M | 4.94M | 4.93M | 0.57M | 5.34M | 6.88M | |||
| Cash from Operations | -0.05M | -1.11M | -1.49M | -0.55M | -1.46M | -3.90M | -2.09M | -3.52M | -3.09M | -2.68M | -3.83M | -5.26M | -4.04M | -1.48M | -1.69M | -5.31M | -5.91M | -11.03M | -9.83M | -11.74M | |||
| Depreciation, Depletion & Amortization | |||||||||||||||||||||||
| Amortizatization of Intangibles | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M | 0.04M | 0.04M | 0.04M | 0.04M | |||||||||||
| Change in Working Capital | |||||||||||||||||||||||
| Change in Accured Expenses | 0.27M | -0.08M | 0.16M | 0.68M | -0.33M | 0.62M | 0.19M | 0.94M | 0.45M | 0.85M | 1.92M | -1.80M | 2.00M | 2.28M | 0.26M | 0.52M | 1.04M | -0.79M | 0.43M | -1.23M | |||
| Other Working Capital Changes | 0.01M | 0.50M | 0.35M | -0.34M | -0.22M | 0.90M | 0.04M | 1.33M | -0.45M | -1.04M | 0.48M | -0.20M | -0.26M | -0.57M | 0.32M | -0.17M | -0.05M | 0.19M | 0.87M | -0.01M | |||
| Investing Activities | |||||||||||||||||||||||
| Capital Expenditures | 0.01M | 0.30M | 0.10M | 0.27M | 0.51M | 0.07M | 0.13M | 0.37M | 0.17M | 0.03M | 0.02M | ||||||||||||
| Change in Acquisitions & Divestments | 3.00M | 7.24M | |||||||||||||||||||||
| Cash from Investing Activities | -0.01M | -0.30M | -0.10M | -0.27M | -0.51M | -0.07M | -0.13M | -0.37M | -6.65M | -4.80M | 2.67M | ||||||||||||
| Financing Activities | |||||||||||||||||||||||
| Other financing activities | 18.65M | 0.17M | -0.17M | 0.00M | 516.00 | 2.00 | 0.03M | 0.01M | |||||||||||||||
| Debt Issuance and Repayment | |||||||||||||||||||||||
| Long-Term Debt Issuances | |||||||||||||||||||||||
| Change in Capital Stock | |||||||||||||||||||||||
| Shares Issued | 0.03M | 0.12M | 0.49M | ||||||||||||||||||||
| Net Shares Issued and Repurchased | 1.03M | 0.01M | 0.59M | 0.74M | 1.57M | 0.03M | 1.39M | 0.11M | |||||||||||||||
| Net Equity Issued and Repurchased | 2.91M | 0.10M | 4.71M | 10.13M | 0.58M | 15.95M | 10.77M | 95.51M | |||||||||||||||
| Misc. | |||||||||||||||||||||||
| Cash from Financing Activities | -0.02M | 18.72M | 2.91M | -0.11M | 0.42M | 0.12M | 4.69M | 10.07M | 0.59M | 15.95M | 10.61M | 95.67M | -0.04M | 155.28M | |||||||||
| Exchange Rate Effect | -0.00M | 621.00 | -0.00M | -0.01M | -0.02M | -157.00 | -562.00 | 0.01M | -0.01M | 0.03M | -0.01M | 0.01M | 0.02M | -0.03M | -0.01M | 0.04M | -0.02M | -0.01M | -0.01M | 0.02M | |||
| Change in Cash | -0.07M | 17.61M | 1.42M | -0.66M | -1.49M | -3.48M | -1.97M | 1.19M | 6.93M | -2.07M | 11.81M | -5.34M | -4.28M | -2.01M | -1.76M | -4.28M | 4.31M | 77.98M | -14.68M | 146.24M | |||
| Free Cash Flow | -0.05M | -1.11M | -1.49M | -0.55M | -1.46M | -3.90M | -2.09M | -3.52M | -3.09M | -2.69M | -4.13M | -5.35M | -4.31M | -1.98M | -1.75M | -5.44M | -6.28M | -11.19M | -9.86M | -11.76M | |||
| Net Cash Flow | -0.07M | 17.61M | 1.42M | -0.65M | -1.46M | -3.48M | -1.97M | 1.18M | 6.98M | -2.10M | 11.82M | -5.35M | -4.31M | -1.98M | -1.75M | -5.44M | 4.33M | 77.99M | -14.67M | 146.22M |